行情

GLPG

GLPG

Galapagos Nv
NASDAQ

实时行情|Nasdaq Last Sale

55.80
+0.40
+0.72%
盘后: 55.50 -0.3 -0.54% 16:01 05/26 EDT
开盘
56.23
昨收
55.40
最高
56.80
最低
55.71
成交量
10.13万
成交额
0
52周最高
81.12
52周最低
46.41
市值
36.63亿
市盈率(TTM)
-31.6865
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解GLPG最新的财务预测,通过GLPG每股收益,每股净资产,每股现金流等数据分析Galapagos Nv近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
42.86%买入
57.14%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测GLPG价格均价为74.02,最高价位100.48,最低价为61.30。
最高100.48
均价74.02
最低61.30
现价55.80
EPS
实际EPS
预期EPS
-1.21-0.82-0.43-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 180
机构持股: 1,474.22万
持股比例: 22.46%
总股本: 6,564.82万
类型机构数股数
增持
24
358.19万
建仓
23
168.37万
减持
31
262.78万
平仓
16
57.11万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.99%
制药与医学研究
+0.43%
高管信息
Chairman/Chief Executive Officer/Director
Paulus Stoffels
President/Chief Financial Officer/Chief Operating Officer/Management Board
Bart Filius
Management Board
Walid Abi-Saab
Management Board
Andre Hoekema
Management Board
Michele Manto
Non-Executive Director
Linda Higgins
Non-Executive Director
Daniel O' Day
Independent Director
Dan Baker
Independent Director
Jerome Contamine
Non-Executive Independent Director
Katrine Bosley
Non-Executive Independent Director
Peter Guenter
Non-Executive Independent Director
Mary Kerr
Non-Executive Independent Director
Howard Rowe
Non-Executive Independent Director
Elisabeth Svanberg
暂无数据
暂无数据
GLPG 简况
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

微牛提供Galapagos NV(NASDAQ-GLPG)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的GLPG股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GLPG股票基本功能。